NL-1 是一种具有抗白血病作用的 mitoNEET 抑制剂。NL-1 抑制 REH 和 REH/Ara-C 细胞生长，IC₅₀ 分别为 47.35 µM 和 56.26 µM。NL-1 介导的白血病细胞死亡需要激活自噬途径。

NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC 50 s of 47.35 μM and 56.26 μM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway.

Solid

MitoNEET

NL-1 (10-100 μM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with IC50s of 29.48 μM, 94.26 μM, respectively. TOM1, BV173, NALM1 and JM1 all have similar IC50 values of around 60 μM for NL-1.
NL-1 (60 μM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death.
NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells.

NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Geldenhuys WJ, et al. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia. J Pharmacol Exp Ther. 2019 Jul;370(1):25-34.

In Vitro: DMSO : 250 mg/mL (745.25 mM; Need ultrasonic)配制储备液